Gastroenterology

Innovative Pipeline Therapies:
A Sea Change in Anti-HCV Therapy

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Innovative Pipeline Therapies: A Sea Change in Anti-HCV Therapy

View Webcast - requires Flash 8 or higher & high-speed Internet
(Tech. Requirements)
View/Download Slides

Presented for attendees of the 56th AASLD Annual Meeting.

This independent CME activity is supported by an educational grant from Vertex Pharmaceuticals Incorporated.

This is not an official function of the American Association for the Study of Liver Diseases.

Dear Colleague,

Anti-HIV therapy underwent a radical change in the mid 1990s with the development of highly active regimens combining the newly developed protease inhibitors with traditional antiretroviral reverse transcriptase inhibitors. With the profound and sustained viral suppression made possible with these new regimens, HIV was transformed from a fatal disease to a chronic disorder manageable for potentially decades. Anti-HCV therapy is now poised at the edge of a similar sea change in therapeutic options. As in the management of HIV a decade ago, potent new agents in the pipeline offer the promise of exciting new combination regimens, resulting in a paradigm shift in the approach to anti-HCV therapy.

Please join us for Innovative Pipeline Therapies: A Sea Change in Anti-HCV Therapy. This multidisciplinary webcast brings together experts in the management of HIV and HCV to discuss how we can apply the lessons learned in the former to the latter. We will discuss the parallels between HIV and HCV infection and therapy, and explore how future anti-HCV therapies can ride the wave begun by anti-HIV therapy. Our specific areas of exploration will include the role of multiple antiviral targets, data from early clinical trials of protease and polymerase inhibitors in HCV infection, and the potential implications of these new agents in clinical practice.

This exciting program promises to be a highly scientific and engaging event that will incorporate shared experiences across specialties, enhance physician education about hepatitis C, and ultimately improve patient care and clinical outcomes.

Sincerely,

CHAIR
John G. McHutchison, MD, FRACP Director, Gastroenterology/Hepatology Research Duke Clinical Research Institute Professor of Medicine Duke University Medical Center Durham, North Carolina

FACULTY
Michael P. Manns, MD Professor and Chairman Department of Gastroenterology, Hepatology and Endocrinology Center of Internal Medicine Medical School of Hannover Hannover, Germany
Jean-Michel Pawlotsky, MD, PhD Professor of Medicine Director, Department of Virology and INSERM U635 Hôpital Henri Mondor Université de Paris XII Créteil, France
Paul A. Volberding, MD Professor and Vice Chair of Medicine University of California, San Francisco Chief of Medical Service San Francisco Veterans Affairs Medical Center San Francisco, California

top

TARGET AUDIENCE

This CME program is designed for gastroenterologists, hepatologists, and other clinicians who treat patients with HCV infection.

ACTIVITY GOAL

The goal of this activity is to provide clinicians with new clinical insights into molecular approaches to anti-HCV therapy utilizing pipeline protease and polymerase inhibitors and to identify the potential role that these agents may play as monotherapy or combination therapy in the future.

LEARNING OBJECTIVES

Applying an understanding of HIV management, incorporate lessons learned from the experience with HIV into improved therapeutic regimens for the treatment of chronic HCV infection.
Utilize knowledge of mechanisms of action in order to understand targeted drug development and the opportunities offered by the new protease and polymerase inhibitors in the treatment of HCV.
Using data from early clinical trials, differentiate potential efficacy and safety considerations of protease and polymerase inhibitors as therapeutic options in the future treatment of patients with HCV infection.
Evaluate the potential role of protease and polymerase inhibitors in future anti-HCV therapy—as monotherapy or in combination with current agents—considering efficacy and safety data, as well as current expert opinion.

top

CME INFORMATION

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.5 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity is planned and implemented in accordance with the ACCME Essential Areas and Policies.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Michael P. Manns, MD, has received grant/research support from Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Gilead Sciences, Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Schering-Plough Corporation; is a consultant for Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Schering-Plough Corporation, and Valeant Pharmaceuticals, International; is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, GlaxoSmithKline, Roche Pharmaceuticals, and Schering-Plough Corporation; and serves on advisory boards for Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals Inc, and Novartis Pharmaceuticals Corporation.

John G. McHutchison, MD, FRACP, has received grant/research support from Akros Pharma Inc, Amgen Inc, Bayer Pharmaceuticals, BioMedicines, Inc, Bristol-Myers Squibb Company, Coley Pharmaceuticals, Inc, Fujisawa Healthcare, Inc, Gilead Sciences, Inc, Human Genome Sciences, IDUN Pharmaceuticals, Inc, Isis Pharmaceuticals, Inc, Ortho Diagnostic Systems, Inc, Prometheus Laboratories, Inc, Ribozyme Pharmaceuticals, Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmaceuticals, Triangle Pharmaceuticals Inc, Valeant Pharmaceuticals, International, and Vertex Pharmaceuticals Incorporated; is a consultant for Valeant Pharmaceuticals International; and is a consultant for and on the speakers bureaus and advisory boards of Amgen Inc, Anadys Pharmaceuticals, Inc, Centocor, Inc, GlaxoSmithKline, Idenix Pharmaceuticals Inc, InterMune Inc, Isis Pharmaceuticals Inc, National Genetics Institute, Inc, Novartis Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories, Ribozyme Pharmaceuticals, Inc, Schering-Plough Corporation, and XTL Biopharmaceuticals Ltd.

Jean-Michel Pawlotsky, MD, PhD, has received grant/research support from Gilead Sciences, Inc and Roche Pharmaceuticals; is a consultant for Abbott Laboratories, Gilead Sciences, Inc, Idenix Pharmaceuticals Inc, Roche Pharmaceuticals, Schering-Plough Corporation, and Vertex Pharmaceuticals, Inc; and is on the speakers bureau of Abbott Laboratories, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.

Paul A. Volberding, MD, is a consultant for Bristol-Myers Squibb Company, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Ortho Biotech Products, LP, Schering-Plough Corporation, and Shire US Inc; and is on the speakers bureau of Gilead Sciences, Inc, and GlaxoSmithKline.

This activity will include a discussion of the unlabeled/unapproved uses of BILN 2061, NM283, SCH 503034, and VX-950.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME activity is supported by an educational grant from
Vertex Pharmaceuticals Incorporated.

top

1738